RBC Europe’s Editas Medicine EDIT Stock Holding History

RBC Europe’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-920	Closed	-$17K	–	632
2022 Q1	$17K	Buy	+920	New	+$17.1K	﹤0.01%	469
2021 Q4	–	Sell	-1,087	Closed	-$44.7K	–	768
2021 Q3	$44.7K	Hold	1,087	–	–	﹤0.01%	596
2021 Q2	$61.6K	Buy	1,087 +920	+551%	+$34K	﹤0.01%	546
2021 Q1	$7.01K	Sell	167 -50	-23%	-$2.85K	﹤0.01%	961
2020 Q4	$15.2K	Buy	217 +50	+30%	+$2.05K	﹤0.01%	792
2020 Q3	$4.69K	Hold	167	–	–	﹤0.01%	912
2020 Q2	$4.94K	Hold	167	–	–	﹤0.01%	870
2020 Q1	$3.31K	Hold	167	–	–	﹤0.01%	861
2019 Q4	$4.95K	Hold	167	–	–	﹤0.01%	903
2019 Q3	$3.8K	Hold	167	–	–	﹤0.01%	921
2019 Q2	$4.13K	Hold	167	–	–	﹤0.01%	934
2019 Q1	$4.08K	Buy	+167	New	+$3.78K	﹤0.01%	949
2018 Q3	–	Sell	-865	Closed	-$31K	–	1144
2018 Q2	$31K	Sell	865 -118	-12%	-$4.18K	﹤0.01%	581
2018 Q1	$32.6K	Hold	983	–	–	﹤0.01%	567
2017 Q4	$30.2K	Hold	983	–	–	﹤0.01%	591
2017 Q3	$23.6K	Buy	+983	New	+$18.7K	﹤0.01%	649

Other funds holding EDIT

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

RBC Europe's EDIT Position: Q2 2022 in Review

RBC Europe sold out of Editas Medicine (EDIT) in Q2 2022, closing a stake of 920 shares — an estimated $17K sold.

RBC Europe first reported a position in EDIT in Q3 2017 and held it in 16 quarters. The position peaked at $61.6K in Q2 2021. 257 funds tracked by Wall St. Rank hold EDIT as of Q2 2022.

RBC Europe reported no remaining Editas Medicine position as of Q2 2022 after selling out during the quarter.
RBC Europe sold 920 Editas Medicine shares in Q2 2022, an estimated $17K.
RBC Europe first reported a position in Editas Medicine in Q3 2017 and held it in 16 quarters.
RBC Europe's Editas Medicine position peaked at $61.6K in Q2 2021.
257 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2022.

Based on RBC Europe's 13F filing for Q2 2022, filed 14 Nov 2022.